Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study

Journal of Neurology

Volumn 261, Issue 12, 2014, Pages 2429-2437

  Arnold, Douglas L ^a,b   Gold, Ralf ^c   Kappos, Ludwig ^d   Bar Or, Amit ^b   Giovannoni, Gavin ^e   Selmaj, Krzysztof ^f   Yang, Minhua ^g   Zhang, Ray ^g   Stephan, Monica ^g   Sheikh, Sarah I ^g   Dawson, Katherine T ^g  

^a NEURORX RESEARCH   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ST JOSEF HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g BIOGEN   (United States)

Author keywords

Delayed release dimethyl fumarate; Magnetic resonance imaging; Magnetization transfer ratio; Multiple sclerosis

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; MYELIN; PLACEBO; DELAYED RELEASE FORMULATION; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DENSITY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN TISSUE; MAGNETIZATION TRANSFER RATIO; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; ADOLESCENT; BRAIN; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PHARMACOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BRAIN; DELAYED-ACTION PREPARATIONS; DIMETHYL FUMARATE; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920971195     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7504-7     Document Type: Article

References (31)

1. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4):907–911
2. Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251(3):261–268. doi:10.1007/s00415-004-0348-9
3. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Bruck W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3):678–692. doi:10.1093/brain/awq386awq386
4. Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF (1993) Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 33(5):480–489. doi:10.1002/ana.410330511
5. Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N (2011) Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler 17(5):541–549. doi:10.1177/1352458510391837
6. Arnold DL, Matthews PM, Francis G, Antel J (1990) Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 14(1):154–159
7. Pike GB, de Stefano N, Narayanan S, Francis GS, Antel JP, Arnold DL (1999) Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. AJNR Am J Neuroradiol 20(5):829–837
8. Filippi M, Rocca MA, Pagani E, Iannucci G, Sormani MP, Fazekas F, Ropele S, Hommes OR, Comi G (2004) European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 61(9):1409–1412. doi:10.1001/archneur.61.9.140961/9/1409
9. Henkelman RM, Stanisz GJ, Graham SJ (2001) Magnetization transfer in MRI: a review. NMR Biomed 14(2):57–64. doi:10.1002/nbm.683
10. Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63(2):254–262. doi:10.1002/ana.21302
11. Chen JT, Kuhlmann T, Jansen GH, Collins DL, Atkins HL, Freedman MS, O’Connor PW, Arnold DL (2007) Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 36(4):1152–1158. doi:10.1016/j.neuroimage.2007.03.073
12. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH (2004) Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56(3):407–415. doi:10.1002/ana.20202
13. Deloire-Grassin MS, Brochet B, Quesson B, Delalande C, Dousset V, Canioni P, Petry KG (2000) In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci 178(1):10–16 (S0022-510X(00)00331-2)
14. Dousset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez-Scarano F, Lavi E, Cohen JA (1992) Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 182(2):483–491. doi:10.1148/radiology.182.2.1732968
15. Merkler D, Boretius S, Stadelmann C, Ernsting T, Michaelis T, Frahm J, Bruck W (2005) Multicontrast MRI of remyelination in the central nervous system. NMR Biomed 18(6):395–403. doi:10.1002/nbm.972
16. Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P (2003) Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 60(8):1073–1081. doi:10.1001/archneur.60.8.1073
17. Laule C, Vavasour IM, Whittall KP, Oger J, Paty DW, Li DK, MacKay AL, Arnold DL (2003) Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 250(8):924–931. doi:10.1007/s00415-003-1115-z
18. Giacomini PS, Levesque IR, Ribeiro L, Narayanan S, Francis SJ, Pike GB, Arnold DL (2009) Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol 66(3):375–381. doi:10.1001/archneurol.2008.57866/3/375
19. Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA (2001) Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 7(1):49–58
20. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097. doi:10.1056/NEJMoa1206328
21. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107. doi:10.1056/NEJMoa1114287
22. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 341(1):274–284. doi:10.1124/jpet.111.190132
23. (2001) International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). J Postgrad Med 47:45–50
24. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html
25. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846. doi:10.1002/ana.20703
26. Barkhof F, Calabresi PA, Miller DH, Reingold SC (2009) Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 5(5):256–266. doi:10.1038/nrneurol.2009.41
27. Button T, Altmann D, Tozer D, Dalton C, Hunter K, Compston A, Coles A, Miller D (2013) Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Mult Scler 19(2):241–244. doi:10.1177/1352458512444915
28. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125(Pt 8):1676–1695
29. Scannevin RH, Bai B, Huang R, Medicetty S, Trapp BD, Rhodes KJ (2013) BG-12 (DIMETHYL fumarate) is neuroprotective in the murine cuprizone/rapamycin model of demyelination and neurodegeneration (P05.184). Neurology 80:05
30. Albrecht P, Bouchachia I, Goebels N et al (2012) Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 9:163. doi:10.1186/1742-2094-9-163
31. Reick C, Ellrichmann G, Thöne J, Scannevin RH, Saft C, Linker RA, Gold R (2014) Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Exp Neurol. doi:10.1016/j.expneurol.2014.04.003